India Montelukast Intermediate Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria) - Growth & Industry Forecast 2025 To 2035
As per Market Research Future analysis, the India Montelukast Intermediate Market size was estimated at 20.0 USD Million in 2024. The Montelukast Intermediate market is projected to grow from 21.2 USD Million in 2025 to 38.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.0% during the forecast period 2025 - 2035
The India montelukast intermediate market is experiencing robust growth driven by increasing demand for respiratory treatments and advancements in manufacturing.
| 2024 Market Size | 20.0 (USD Million) |
| 2035 Market Size | 38.0 (USD Million) |
| CAGR (2025 - 2035) | 6.01% |
Merck & Co (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Aurobindo Pharma (IN), Cipla (IN), Hikma Pharmaceuticals (GB), Sandoz (CH), Zydus Cadila (IN)
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The India Montelukast Intermediate Market is currently experiencing notable developments, driven by increasing demand for asthma and allergy medications. This market is characterized by a growing awareness of respiratory diseases and the need for effective treatments. The rise in healthcare expenditure and the expansion of pharmaceutical manufacturing capabilities in India contribute to the market's growth. Additionally, the regulatory environment appears to be supportive, fostering innovation and the introduction of new products. As a result, the montelukast intermediate market is poised for further expansion, with various stakeholders actively participating in this evolving landscape. Moreover, the montelukast intermediate market is witnessing a shift towards sustainable practices and green chemistry. Manufacturers are increasingly focusing on environmentally friendly production methods, which may enhance their competitive edge. The emphasis on quality and compliance with international standards is also becoming more pronounced. This trend suggests that companies are not only aiming for profitability but are also considering their environmental impact. Overall, the montelukast intermediate market is likely to continue evolving, reflecting broader trends in healthcare and sustainability.
The montelukast intermediate market is experiencing a surge in demand for medications targeting respiratory conditions. This trend is largely influenced by an increase in the prevalence of asthma and allergies, prompting healthcare providers to seek effective treatment options. As awareness of these conditions grows, the market is expected to expand, with more pharmaceutical companies investing in research and development.
There is a noticeable shift towards sustainable manufacturing within the montelukast intermediate market. Companies are adopting environmentally friendly production methods to reduce their ecological footprint. This trend not only aligns with global sustainability goals but also appeals to consumers who are increasingly conscious of environmental issues.
The regulatory landscape surrounding the montelukast intermediate market appears to be conducive to innovation. Government policies are encouraging the development of new formulations and production techniques. This supportive environment may lead to the introduction of advanced products, enhancing the overall market competitiveness.
An increase in healthcare expenditure in India is likely to bolster the montelukast intermediate market. With the government and private sectors investing more in healthcare infrastructure and services, access to medications is improving. The healthcare expenditure in India is projected to reach approximately 3.6% of GDP by 2025, which may lead to greater availability of montelukast and related treatments. This trend suggests that more patients will have access to essential medications, thereby increasing the demand for montelukast intermediates. As healthcare policies evolve to prioritize respiratory health, the montelukast intermediate market is expected to benefit from this upward trajectory in spending.
The montelukast intermediate market is influenced by the evolving regulatory framework in India, which aims to promote innovation while ensuring safety and efficacy. The Drug Controller General of India (DCGI) has been actively working to streamline approval processes for new drugs and intermediates. This regulatory support is expected to encourage more companies to enter the montelukast intermediate market, fostering competition and innovation. Furthermore, the emphasis on quality assurance and compliance with international standards may enhance the reputation of Indian manufacturers in the global market. As a result, the montelukast intermediate market could see an influx of new players and products, driving growth and diversification.
The montelukast intermediate market is likely to benefit from the growing awareness of preventive healthcare among the Indian population. As individuals become more informed about the importance of managing respiratory conditions, there is a shift towards proactive treatment approaches. Educational campaigns and initiatives by healthcare organizations are emphasizing the significance of early intervention and consistent management of asthma and allergies. This heightened awareness is expected to drive demand for montelukast, consequently impacting the montelukast intermediate market positively. As more patients seek effective solutions for their respiratory issues, the market may witness an increase in production and distribution of montelukast intermediates.
Technological advancements in pharmaceutical manufacturing processes are significantly impacting the montelukast intermediate market. Innovations such as continuous manufacturing and process optimization are enhancing production efficiency and reducing costs. In India, the pharmaceutical sector is projected to grow at a CAGR of around 10% over the next few years, which may lead to increased investments in the montelukast intermediate market. These advancements not only improve the quality of the intermediates but also ensure compliance with stringent regulatory standards. As manufacturers adopt these technologies, the montelukast intermediate market is likely to benefit from improved supply chain dynamics and reduced lead times, ultimately meeting the rising demand for montelukast.
The montelukast intermediate market is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis in India. Reports indicate that approximately 10-15% of the Indian population suffers from asthma, leading to a heightened demand for effective treatments. This trend is likely to drive the montelukast intermediate market as pharmaceutical companies seek to produce more montelukast, a key medication for managing these conditions. The increasing awareness of respiratory health and the need for preventive care further contribute to this demand. As healthcare providers emphasize the importance of managing allergies, the montelukast intermediate market is positioned to expand, catering to the needs of a growing patient population.
Asthma Treatment holds a significant share of the India montelukast intermediate market due to the high prevalence of asthma conditions among the population. In contrast, Allergic Rhinitis Treatment is gaining traction with an increasing number of diagnosed cases, leading to a competitive landscape where both segments are vital. The Chronic Obstructive Pulmonary Disease segment, though valuable, trails behind in market share, indicating varied demand across applications. The growth trends for these segments are largely driven by rising awareness, better diagnosis, and treatment options available. Moreover, the increasing pollution levels and changing lifestyle habits heighten the need for effective asthma and allergic rhinitis therapies, propelling the growth of these markets. Regulatory approvals and innovative formulations are expected to further stimulate expansion in the India montelukast intermediate market.
Asthma Treatment (Dominant) vs. Allergic Rhinitis Treatment (Emerging)
Asthma Treatment is the dominant segment in the India montelukast intermediate market, primarily due to the widespread nature of asthma, making it a priority for healthcare providers. This segment benefits from established treatment protocols and a loyal patient base that ensures steady demand. On the other hand, Allergic Rhinitis Treatment is emerging rapidly, driven by an increase in allergic conditions and heightened health awareness among consumers. The growth of this segment is further supported by new product development and marketing strategies tailored to engage potential users. Both segments are integral to the market, signifying varying patient needs and emphasizing the need for continued innovation.
In the formulation type segment of the India montelukast intermediate market, tablets account for the largest market share due to their established preference among consumers and healthcare professionals. Granules and oral solutions have smaller shares but cater to specific demographics like pediatric patients and those with swallowing difficulties. Tablets are favored for their convenience, stability, and ease of administration, which boosts their penetration in the market. The growth trends within this segment indicate a burgeoning demand for granules, attributed to an increase in the preference for tailored medication delivery in younger populations who may struggle with solid dosages. Additionally, oral solutions are gaining traction due to their efficacy and ease of use, particularly in specific health conditions. Innovations in formulation technologies are expected to propel growth across these sub-segments, enhancing market dynamics substantially.
Tablets: Dominant vs. Granules: Emerging
Tablets represent the dominant formulation type in the India montelukast intermediate market, characterized by their portability, longer shelf life, and consumer familiarity. This dominance is largely supported by effective marketing and established healthcare practices. In contrast, granules are considered an emerging option, capturing the attention of manufacturers due to their flexible dosing and appeal to children and patients with difficulty swallowing pills. As awareness increases regarding the benefits of personalized medicine, granules are likely to witness accelerated growth. The market positioning of both formulations reflects a blend of consumer preferences and clinical effectiveness, with tablets heralded for stability, while granules embrace innovation and adaptability.
The route of administration segment in the India montelukast intermediate market showcases a diverse distribution of market shares. Oral administration continues to dominate this segment, reflecting the strong preference among patients and healthcare providers for the convenience and ease of ingestion. Inhalation, while accounting for a smaller share, is rapidly gaining traction due to its targeted delivery method, which is appealing in managing respiratory conditions. Growth trends indicate that the oral route will maintain its leading position; however, the inhalation route is registered as the fastest-growing segment. The increasing prevalence of asthma and allergic rhinitis in India is driving demand for inhalation therapies. Additionally, advancements in inhalation devices and formulation technologies are enhancing the attractiveness of inhaled options, making them a preferred choice for patients seeking effective and rapid relief.
Oral (Dominant) vs. Inhalation (Emerging)
Oral administration is the dominant route in the India montelukast intermediate market, mainly due to its well-established efficacy and patient acceptance. It allows for easier dosing and adherence, which is crucial for chronic conditions like asthma. On the other hand, inhalation is emerging as a significant player, primarily through innovations in aerosol and nebulizer technology that improve drug delivery efficiency. The inhalation route is particularly favored in acute scenarios where rapid relief is essential. As awareness of respiratory health grows, both routes are poised for sustained growth, with the oral route likely remaining popular while inhalation captures a growing share of the market.
In the India montelukast intermediate market, the distribution of sales through various channels shows that pharmacies dominate the landscape, capturing the largest share due to their accessibility and established trust among consumers. Online pharmacies have emerged as a significant contender, appealing to a tech-savvy demographic seeking convenience and wider product availability. Growth trends indicate a marked shift towards online pharmacies, driven by the increasing adoption of e-commerce and digital health solutions. The COVID-19 pandemic has accelerated this trend, enhancing the acceptance of online purchasing for prescription medications. Pharmacies continue to hold their ground, yet online platforms are predicted to experience the highest growth rate as they innovate to meet consumer needs and streamline delivery processes.
Pharmacies: Dominant vs. Online Pharmacies: Emerging
Pharmacies serve as the dominant distribution channel in the India montelukast intermediate market, leveraging their established networks and direct interactions with patients. Their ability to offer personalized service, medication counseling, and immediate accessibility contributes significantly to their market position. Conversely, online pharmacies represent an emerging channel, characterized by their rapid growth in consumer base and flexibility in delivery options. These platforms cater to a younger audience and those seeking the convenience of home delivery, thus positioning themselves as essential players in the evolving market landscape. The competition between these two segments illustrates a dynamic shift where online pharmacies are gradually capturing market share, while pharmacies maintain their relevance through exceptional service.
Get more detailed insights about India Montelukast Intermediate Market Request Free Sample
The montelukast intermediate market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Merck & Co (US), Mylan N.V. (US), and Aurobindo Pharma (IN) are actively pursuing strategies that enhance their market positioning. Merck & Co (US) focuses on research and development to innovate its product offerings, while Mylan N.V. (US) emphasizes strategic acquisitions to bolster its portfolio. Aurobindo Pharma (IN) is leveraging its manufacturing capabilities to optimize production costs and expand its market reach, thereby collectively influencing the competitive dynamics of the market. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and competitive pricing, although the influence of major players remains significant in shaping market trends and consumer preferences. In October 2025, Merck & Co (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new formulation of montelukast, aimed at improving patient compliance and therapeutic outcomes. This collaboration is likely to enhance Merck's competitive edge by integrating advanced biotechnological innovations into its product line, thereby addressing unmet medical needs in the market. In September 2025, Aurobindo Pharma (IN) expanded its manufacturing facility in Hyderabad, which is expected to increase its production capacity for montelukast intermediates. This expansion not only positions Aurobindo to meet rising demand but also reflects its commitment to maintaining high-quality standards and regulatory compliance, which are crucial in the pharmaceutical industry. In August 2025, Mylan N.V. (US) launched a new digital platform aimed at streamlining its supply chain processes for montelukast intermediates. This initiative is indicative of a broader trend towards digital transformation within the industry, as companies seek to enhance operational efficiency and responsiveness to market changes. As of November 2025, current competitive trends in the montelukast intermediate market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into operations. Strategic alliances are becoming more prevalent, allowing companies to pool resources and expertise to drive innovation. Looking ahead, the competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, supply chain reliability, and innovative product development, which may redefine market dynamics in the coming years.
The India Montelukast Intermediate Market has witnessed significant developments in recent months, with key players like Intas Pharmaceuticals, Torrent Pharmaceuticals, and Dr Reddy's Laboratories expanding their production capacities due to rising demand. In October 2023, Intas announced its plans to enhance its manufacturing facilities in Gujarat, aiming to increase output for key intermediates, including Montelukast, to further strengthen its position in the market.
Additionally, Torrent Pharmaceuticals has successfully received regulatory approvals for new Montelukast formulations, which are expected to boost its market share. In terms of mergers and acquisitions, Alkem Laboratories completed an acquisition of a local biotechnology firm in September 2023 to bolster its R&D capabilities in respiratory medications, drawing focus toward Montelukast derivatives.
Moreover, the overall market valuation for Montelukast in India has seen a steady growth of approximately 12% year-on-year, attributed to a rise in asthma and allergy cases. The competitive landscape remains active with companies like Aurobindo Pharma and Cipla also looking to innovate in the respiratory therapeutics segment. Major advancements in manufacturing technologies are enhancing the efficiency and cost-effectiveness of Montelukast production across the sector.
The Montelukast Intermediate Market is projected to grow at a 6.01% CAGR from 2025 to 2035, driven by increasing demand for asthma treatments and regulatory support.
New opportunities lie in:
By 2035, the montelukast intermediate market is expected to achieve robust growth and increased market share.
| MARKET SIZE 2024 | 20.0(USD Million) |
| MARKET SIZE 2025 | 21.2(USD Million) |
| MARKET SIZE 2035 | 38.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.01% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck & Co (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Aurobindo Pharma (IN), Cipla (IN), Hikma Pharmaceuticals (GB), Sandoz (CH), Zydus Cadila (IN) |
| Segments Covered | Application, Formulation Type, Route of Administration, Distribution Channel |
| Key Market Opportunities | Growing demand for montelukast intermediates driven by increased respiratory disease prevalence and regulatory support. |
| Key Market Dynamics | Rising demand for montelukast intermediates driven by regulatory shifts and increasing respiratory health awareness in India. |
| Countries Covered | India |
The overall market valuation was $20.0 Million in 2024.
The projected valuation for 2035 is $38.0 Million.
The expected CAGR during the forecast period 2025 - 2035 is 6.01%.
Key players include Merck & Co, Mylan N.V., Teva Pharmaceutical Industries Ltd, Aurobindo Pharma, Cipla, Hikma Pharmaceuticals, Sandoz, and Zydus Cadila.
The main application segments include Asthma Treatment, Allergic Rhinitis Treatment, and Chronic Obstructive Pulmonary Disease.
The market valuation for Asthma Treatment was $8.0 Million in 2024.
The projected market valuation for Oral administration by 2035 is $22.0 Million.
Available formulation types include Tablets, Granules, and Oral Solution.
Distribution channels such as Pharmacies, Online Pharmacies, and Hospitals play a crucial role, with Pharmacies valued at $10.0 Million in 2024.
The market appears to be on a growth trend, with a projected increase to $38.0 Million by 2035.
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
